INCLINE VILLAGE, Nev.,
July 28, 2014 /PRNewswire/ -- PDL
BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the
Company will release its second quarter 2014 financial results for
the period ended June 30, 2014, on
Monday, August 11, 2014, after market
close. PDL's management will host a conference call and webcast
that day at 4:30 p.m. Eastern Time to
discuss the financial results. A slide presentation relating
to the call will be available via the webcast link on the PDL
website.
Conference Call Details
To access the live conference
call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The
conference ID is 79689642. Please dial in approximately 10 minutes
prior to the start of the call. A telephone replay will be
available beginning approximately one hour after the call through
August 19, 2014, and may be accessed
by dialing (855) 859-2056 from the United
States and Canada or (404)
537-3406 internationally. The replay passcode is 79689642.
To access the live and subsequently archived webcast of the
conference call, go to the Company's website at http://www.pdl.com
and go to "Events & Presentations." Please connect to the
website at least 15 minutes prior to the call to allow for any
software download that may be necessary.
About PDL BioPharma, Inc.
PDL BioPharma manages a
portfolio of patents and royalty assets, consisting primarily of
its Queen et al. antibody humanization patents and license
agreements with various biotechnology and pharmaceutical companies.
PDL pioneered the humanization of monoclonal antibodies and, by
doing so, enabled the discovery of a new generation of targeted
treatments for cancer and immunologic diseases for which it
receives significant royalty revenue. PDL is currently focused on
intellectual property asset management, acquiring new income
generating assets, and maximizing value for its shareholders.
The company was formerly known as Protein Design Labs, Inc. and
changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in
1986 and is headquartered in Incline
Village, Nevada.
In 2011, PDL initiated a strategy to bring in new income
generating assets from the healthcare sector. To accomplish this
goal, PDL seeks to provide non-dilutive growth capital and
financing solutions to late stage public and private healthcare
companies and offers immediate financial monetization of royalty
streams to companies, academic institutions, and inventors. PDL
continues to pursue this strategic initiative for which it has
already deployed approximately $715
million to date. PDL is focused on the quality of the income
generating assets and potential returns on investment.
For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
Logo -
http://photos.prnewswire.com/prnh/20110822/SF55808LOGO
SOURCE PDL BioPharma, Inc.